|
1
|
Tageja N and Nagi J: Bendamustine:
Something old, something new. Cancer Chemother Pharmacol.
66:413–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hartmann M and Zimmer C: Investigation of
cross-link formation in DNA by the alkylating cytostatic IMET 3106,
3393 and 3943. Biochim Biophys Acta. 287:386–389. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strumberg D, Harstrick A, Doll K, Hoffmann
B and Seeber S: Bendamustine hydrochloride activity against
doxorubicin-resistant human breast carcinoma cell lines. Anticancer
Drugs. 7:415–421. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leoni LM, Bailey B, Reifert J, Bendall HH,
Zeller RW, Corbeil J, Elliott G and Niemeyer CC: Bendamustine
(Treanda) displays a distinct pattern of cytotoxicity and unique
mechanistic features compared with other alkylating agents. Clin
Cancer Res. 14:309–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Knauf WU, Lissichkov T, Aldaoud A,
Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G,
Gercheva L, Goranov S, et al: Phase III randomized study of
bendamustine compared with chlorambucil in previously untreated
patients with chronic lymphocytic leukemia. J Clin Oncol.
27:4378–4384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedberg JW, Cohen P, Chen L, Robinson
KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES,
Williams ME, et al: Bendamustine in patients with
rituximab-refractory indolent and transformed non-Hodgkin's
lymphoma: Results from a phase II multicenter, single-agent study.
J Clin Oncol. 26:204–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohmachi K, Niitsu N, Uchida T, Kim SJ,
Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, et al:
Multicenter phase II study of bendamustine plus rituximab in
patients relapsed or refractory diffuse large B-cell lymphoma. J
Clin Oncol. 31:2103–2109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCloskey JK, Broome CM and Cheson BD:
Safe and effective treatment of aggressive non-Hodgkin lymphoma
with rituximab and bendamustine in patients with severe liver
impairment. Clin Adv Hematol Oncol. 11:184–188. 2013.PubMed/NCBI
|
|
9
|
Rummel MJ, Niederle N, Maschmeyer G, Banat
GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M,
Balser C, et al: Bendamustine plus rituximab versus CHOP plus
rituximab as first-line treatment for patients with indolent and
mantle-cell lymphomas: An open-label, multicentre, randomized,
phase 3 non-inferiority trial. Lancet. 381:1203–1210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiraoka N, Kikuchi J, Yamauchi T, Koyama
D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, et al:
Purine analog-like properties of bendamustine underlie rapid
activation of DNA damage response and synergistic effects with
pyrimidine analogues in lymphoid malignancies. PLoS One.
9:e906752014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Visco C, Finotto S, Zambello R, Paolini R,
Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES and
Rodeghiero F: Combination of rituximab, bendamustine, and
cytarabine for patients with mantle-cell non-Hodgkin lymphoma
ineligible for intensive regimens or autologous transplantation. J
Clin Oncol. 31:1442–1449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hattori M, Kawakami K, Akimoto M, Takenaga
M, Suzumiya J and Honma Y: Antitumor effect of Japanese apricot
extract (MK615) on human cancer cells in vitro and in vivo through
a reactive oxygen species-dependent mechanism. Tumori. 99:239–248.
2013.PubMed/NCBI
|
|
13
|
Adachi M, Suzuki Y, Mizuta T, Osawa T,
Adachi T, Osaka K, Suzuki K, Shiojima K, Arai Y, Masuda K, et al:
The ‘Prunus mume Sieb. et Zucc’ (Ume) is a rich natural source of
novel anti-cancer substance. Int J Food Prop. 10:375–384. 2007.
View Article : Google Scholar
|
|
14
|
Gutterman JU, La HT, Yang P, Haridas V,
Gaikwad A and Marcus S: Effects of the tumor inhibitory
triterpenoid avicin G on cell integrity, cytokinesis, and protein
ubiquitination in fission yeast. Proc Natl Acad Sci USA. 102:pp.
12771–12776. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamai H, Sawada N, Yoshida T, Seike J,
Takizawa H, Kenzaki K, Miyoshi T, Kondo K, Bando Y, Ohnishi Y and
Tangoku A: Triterpenes augment the inhibitory effects of anticancer
drugs on growth of human esophageal carcinoma cells in vitro and
suppress experimental metastasis in vivo. Int J Cancer.
125:952–960. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushita S, Tada K, Kawahara K, Kawai K,
Hashiguchi T, Maruyama I and Kanekura T: Advanced malignant
melanoma responds to Prunus mume Sieb. Et Zucc (Ume) extract: Case
report and in vitro study. Exp Ther Med. 1:569–574. 2010.PubMed/NCBI
|
|
17
|
Niitsu N, Higashihara M and Honma Y: Human
B-cell lymphoma cell lines are highly sensitive to apoptosis
induced by all-trans retinoic acid and interferon-gamma. Leuk Res.
26:745–755. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weber AM and Ryan AJ: ATM and ATR as
therapeutic targets in cancer. Pharmacol Ther. 149:124–138. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ackler S, Mitten MJ, Chen J, Foster K, Jin
S, Phillips DC, Schlessinger S, Wang B, Leverson JD and Boghaert
ER: Navitoclax (ABT-263) and bendamustine ± rituximab induce
enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J
Pharmacol. 167:881–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu B, Li J, Pan J, Huang B, Liu J and
Zheng D: Everolimus enhances the cytotoxicity of bendamustine in
multiple myeloma cells through a network of pro-apoptotic and
cell-cycle-progression regulatory proteins. Acta Biochim Biophys
Sin (Shanghai). 45:683–691. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Q, Chen LS, Neelapu SS and Gandhi V:
Combination of Pim kinase inhibitor SGI-1776 and bendamustine in
B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 13 Suppl 2:S355–S362.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai B, Lyu H, Huang J, Wang S, Lee CK, Gao
C and Liu B: Combination of bendamustine and etinostat
synergistically inhibits proliferation of multiple myeloma cells
via induction of apoptosis and DNA damage response. Cancer Lett.
335:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaneko N, Mitsuoka K, Amino N, Yamanaka K,
Kita A, Mori M, Miyoshi S and Kuromitsu S: Combination of YM155, a
surviving suppressant, with bendamustine and rituximab: A new
combination therapy to treat relapse/refractory diffuse large
B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng Y, Wang N, Zhu M, Feng Y, Li H and
Tsao S: Recent progress on anticancer candidates in patents of
herbal medicinal products. Recent Pat Food Nutr Agric. 3:30–48.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fokas E, Prevo R, Hammond EM, Brunner TB,
McKenna WG and Muschel RJ: Targeting ATR in DNA damage response and
cancer therapeutics. Cancer Treat Rev. 40:109–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
